Literature DB >> 20951636

Anti-Tax antibody levels in asymptomatic carriers, oligosymptomatic carriers, patients with rheumatologic disease or with HAM/TSP do not correlate with HTLV-1 proviral load.

Jaqueline Gontijo de Souza1, Flávio Guimarães da Fonseca, Marina Lobato Martins, Camila Pacheco Silveira Martins, Luciana Debortoli de Carvalho, Jordana Grazziela Alves Coelho-dos-Reis, Anna Bárbara Freitas Carneiro-Proietti, Olindo Assis Martins-Filho, Edel Figueiredo Barbosa-Stancioli.   

Abstract

BACKGROUND: HTLV-1 infects millions of people around the world and induces myelopathy (HAM/TSP), adult T-cell leukemia (ATL) or other inflammatory or rheumatologic diseases. The host-virus interaction causes asymptomatic carriers to develop HAM/TSP. Biomarkers are needed to predict patients who are at risk for HAM/TSP. Tax is highly immunogenic and is a major target protein recognized by cytotoxic T lymphocytes. Anti-Tax antibodies are involved in HAM/TSP pathogenesis.
OBJECTIVES: To assess anti-Tax IgG reactivity with a flow cytometry assay (FCA) using an infection/transfection system with Vaccinia virus and pLW44/Tax-expressing Tax and to correlate the anti-Tax response and the HTLV-1 proviral load. STUDY
DESIGN: : We enrolled 81 individuals: 9 HTLV-1 seronegative (NP) and 72 HTLV-1 positive (23 HTLV-1 asymptomatic carriers (AC), 12 oligosymptomatic patients (OL), 7 with rheumatologic diseases (DR) and 30 with HAM/TSP (HT)). Anti-Tax reactivity was assessed by FCA, and HTLV-1 proviral load was measured with real time PCR.
RESULTS: The HT and DR groups showed greater anti-Tax IgG reactivity (p<0.001 and p<0.05 comparing HT to the OL and AC group, respectively; p<0.05 comparing DR to the OL group), and the reactivity in the DR+HT group was significantly different when compared to the AC group (p<0.05) and to the OL group (p<0.001). The proviral load was higher in the HT group compared to the OL (p<0.001) and in the HT+DR group compared to OL (p<0.001). There was no correlation between anti-Tax IgG reactivity and proviral load in any of the HTLV-1-infected groups.
CONCLUSION: These findings suggest that although anti-Tax IgG reactivity and the HTLV-1 proviral load are important markers of the development of HTLV-1-associated diseases, their levels are not correlated.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20951636     DOI: 10.1016/j.jcv.2010.09.007

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  4 in total

1.  Multi-Epitope Protein as a Tool of Serological Diagnostic Development for HTLV-1 and HTLV-2 Infections.

Authors:  Gabriela de Melo Franco; Anderson Santos da Rocha; Laura Jorge Cox; Danielle Soares de Oliveira Daian E Silva; Débora Marques da Silveira E Santos; Marina Lobato Martins; Luis Claudio Romanelli; Ricardo Ishak; Antonio C R Vallinoto; Maria Rosa Q Bomfim; Adele Caterino-de-Araujo; Jordana G A Coelho-Dos-Reis; Flávio Guimarães da Fonseca; Edel Figueiredo Barbosa-Stancioli
Journal:  Front Public Health       Date:  2022-05-23

2.  First Description of Seronegative HTLV-1 Carriers in Argentina.

Authors:  Sandra Gallego; María C Frutos; Sebastián Blanco; Gonzalo Castro; Marcos Balangero; David Elías Panigo; Arnaldo Mangeaud; Carlos Remondegui; Anderson Santos Rocha; Gabriela Melo Franco; Marina Lobato Martins; Edel Figueiredo Barbosa-Stancioli; Silvia Nates
Journal:  Am J Trop Med Hyg       Date:  2020-04       Impact factor: 2.345

3.  Differential role of PKC-induced c-Jun in HTLV-1 LTR activation by 12-O-tetradecanoylphorbol-13-acetate in different human T-cell lines.

Authors:  Ammar Abou-Kandil; Rachel Chamias; Mahmoud Huleihel; W T Godbey; Mordechai Aboud
Journal:  PLoS One       Date:  2012-01-27       Impact factor: 3.240

4.  Leukotrienes are upregulated and associated with human T-lymphotropic virus type 1 (HTLV-1)-associated neuroinflammatory disease.

Authors:  Bruno Caetano Trindade; Carlos Artério Sorgi; Larissa Deadame de Figueiredo Nicolete; Tathiane Maistro Malta; Mariana Tomazini Pinto; Osvaldo Massaiti Takayanagui; Dimas Tadeu Covas; Olindo Assis Martins Filho; Simone Kashima; Lúcia Helena Faccioli
Journal:  PLoS One       Date:  2012-12-20       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.